Renal Atherosclerotic Revascularization Evaluation: RAVE Study
Hypertension, Renovascular
About this trial
This is an interventional treatment trial for Hypertension, Renovascular focused on measuring Hypertension, Renal artery stenosis, Kidney disease, Renal vascular disease, Atherosclerosis
Eligibility Criteria
Inclusion Criteria: Systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg despite at least 3 antihypertensive medications Systolic blood pressure >140 mmHg and/or diastolic blood pressure > 90 mmHg on two antihypertensives with: a rise in creatinine > 20% after initiation of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB); the sudden onset of hypertension occurring after age 55; hypokalemia or the presence of an abdominal bruit; a history of flash pulmonary edema; or any three of: peripheral vascular disease, coronary artery disease, cerebrovascular disease, smoking, hyperlipidemia, diabetes or male gender. Exclusion Criteria: Serum creatinine > 220 umol/L or estimated glomerular filtration rate (GFR) by Cockroft-Gault equation < 20 ml/min Patients who are unwilling or unable to give informed consent Known contraindication to renal revascularization such as anaphylactic allergy to contrast dye An abdominal aortic aneurysm requiring surgery A single functioning kidney; a total occlusion of the renal artery or renal artery stenosis due to fibromuscular dysplasia. Previous revascularization
Sites / Locations
- Sunnybrook & Women's College Health Sciences Centre